ArMan 

ArMan is a co-activator of DC-SIGN (CD209) and TLR7. ArMan can selectively bind to DC-SIGN, promoting receptor-mediated endocytosis of the virus-like particle (VLP) platform, thereby enhancing co-binding with TLR7. ArMan can drive dendritic cell activation, shifting the immune response from humoral immunity to type 1 cellular immunity. ArMan can be used in melanoma research^[1].

ArMan (8 nM; 30 min) displayed by VLPs exhibits enhanced colocalization with DC-SIGN and TLR7 in human monocyte-derived dendritic cells following 30 min of incubation^[1].
ArMan (8 nM; 24 h) displayed by VLPs induces robust activation of human monocyte-derived dendritic cells, with significantly increased surface expression of CD40, CD80, CD83, and CD86 after 24 h of incubation, dependent on DC-SIGN binding^[1].
ArMan (8 nM; 6 h) displayed by VLPs upregulate TLR7-associated gene expression and hallmark DC activation pathways in human monocyte-derived dendritic cells after 6 h of incubation^[1].
ArMan (8 nM; 32 h) displayed by VLPs induce significantly higher secretion of pro-inflammatory cytokines (TNF-α, IL-6, CXCL10, IL-8, IL-12p70) by human monocyte-derived dendritic cells after 32 h of incubation, dependent on DC-SIGN engagement^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ArMan (s.c. or i.p.; days 3, 9, 15) delivered via VLPs generates robust, tumor antigen-specific Th1 CD4⁺ and CD8⁺ T cells capable of tumor infiltration, significantly inhibiting melanoma tumor growth, extending survival, and providing long-term protection against tumor recurrence in mice^[1].
ArMan (s.c. or i.p.; days 3, 9, 15) delivered via VLPs functions as a self-adjuvanting cancer vaccine component, inducing robust tumor antigen-specific CD8⁺ T cell responses and supporting anti-tumor efficacy in mice without the need for additional adjuvants^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

379.40

C₁₉H₂₅NO₇

OC[C@H]([C@H]([C@@H]1O)O)O[C@@H]([C@H]1O)OC2=CC=C(CCNC(CCC#C)=O)C=C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Lensch V, Gabba A, Hincapie R, et al.. Carbohydrate-Lectin Interactions Reprogram Dendritic Cells to Promote Type 1 Anti-Tumor Immunity. ACS nano. 2024 Oct 01;18(39):26770-26783.  [Content Brief]